THERAPY OF LOCALLY ADVANCED NONRESECTABLE RECTAL CANCER Russian patent published in 2009 - IPC A61N5/00 A61K31/513 A61K31/282 A61K31/196 A61K31/245 A61K31/57 A61K31/4152 A61K31/714 A61P35/00 A61K31/7036 A61K31/704 A61K31/765 A61K31/165 A61K35/16 A61K35/14 A61K38/21 

FIELD: medicine.

SUBSTANCE: in 1^st, 9^th, 17^th and 24^th days of therapy, 5-fluorouracil 750 mg and cisplatin 30 mg incubated with autoblood are introduced intravenously. In 7^th, 15^th and 23^rd days, cisplatin 10 mg incubated with autoplasma, Novocaine 0.5% 20 ml, hydrocortisone 1.0 ml, analginum 50% 2.0 ml, vitamin B12 1.0 ml and gentamycin 1.6 g are introduced into presacral of small pelvis. From 10^th to 14^th days, 2 hours prior to radiotherapy session, a mixture containing Doxorubicin-Ebewe 5 mg, Viferon ointment 2.5 mg, Vinilin 2 ml, Synthomycin emulsion 2 ml and Dimexide 5% 4 ml is supplied to primary-site tumour through a perforated rubber tube. From 18^th to 22^th days, a mixture containing Mitomycin C 2.5 mg, Viferon ointment 2.5 mg, Vinilin 2 ml, Synthomycin emulsion 2 ml and Dimexide 5% 4 ml is supplied to primary-site tumour through a perforated rubber tube. After an 14-day recess, the therapeutical actions are repeated once again as specified.

EFFECT: involution of tumour, reduced radiation exposure and toxic by-effects of antitumour therapy.

1 ex